



US 20210206714A1

(19) **United States**(12) **Patent Application Publication**
Ginty et al.(10) **Pub. No.: US 2021/0206714 A1**(43) **Pub. Date: Jul. 8, 2021**(54) **COMPOSITIONS AND METHODS FOR
REDUCING TACTILE DYSFUNCTION,
ANXIETY, AND SOCIAL IMPAIRMENT**(71) Applicant: **President and Fellows of Harvard
College, Cambridge, MA (US)**(72) Inventors: **David D. Ginty, Boston, MA (US);
Lauren L. Orefice, Boston, MA (US);
Jinbo Lee, Andover, MA (US)**(73) Assignee: **President and Fellows of Harvard
College, Cambridge, MA (US)**(21) Appl. No.: **17/056,069**(22) PCT Filed: **May 22, 2019**(86) PCT No.: **PCT/US2019/033581**

§ 371 (c)(1),

(2) Date: **Nov. 17, 2020****Related U.S. Application Data**(60) Provisional application No. 62/823,360, filed on Mar.
25, 2019, provisional application No. 62/674,770,
filed on May 22, 2018.**Publication Classification**(51) **Int. Cl.****C07C 229/48** (2006.01)**A61P 25/04** (2006.01)**A61P 25/02** (2006.01)(52) **U.S. Cl.****CPC** **C07C 229/48** (2013.01); **A61P 25/02**
(2018.01); **A61P 25/04** (2018.01)**ABSTRACT**

The present invention features novel peripherally-restricted isoguvacine analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.

Tactile PPI

